Nguyen, T. T. T., Gao, Q., Mun, J.-Y., Zhu, Z., Shu, C., Naim, A., Rogava, M., Izar, B., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2024). Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells, 13(13), 1155. https://doi.org/10.3390/cells13131155

Henick, B. S., & Moy, R. H. (2024). TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer. JCO Precision Oncology, 8. https://doi.org/10.1200/po.24.00344

Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J.-W., Cuella-Martin, R., Hayward, S. B., Kesner, J. S., Ghasemzadeh, A., Nambiar, T. S., Ho, P., Rialdi, A., Hebrard, M., Li, Y., … Ciccia, A. (2024). SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861-881.e32. https://doi.org/10.1016/j.cell.2024.01.008

Melms, J. C., Ho, P., Rogava, M., & Izar, B. (2023). From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6. Genes & Immunity, 25(1), 82–84. https://doi.org/10.1038/s41435-023-00224-9

Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., Van Tine, B. A., Conley, A. P., Read, W. L., Riedel, R. F., Burgess, M. A., Glod, J., Davis, E. J., Merriam, P., Naqash, A. R., Fino, K. K., Miller, B. L., Wilsker, D. F., Begum, A., … Doroshow, J. H. (2023). Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal of Medicine, 389(10), 911–921. https://doi.org/10.1056/nejmoa2303383

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z., Kyrysyuk, O., Amin, A. D., Caprio, L., Fullerton, B. T., Soni, R. K., Ager, C. R., Biermann, J., Wang, Y., Khosravi-Maharlooei, M., Zanetti, G., Mu, M., Fatima, H., … Izar, B. (2023). The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell, 41(7), 1207-1221.e12. https://doi.org/10.1016/j.ccell.2023.05.014

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551

Moore, E. K., Strazza, M., & Mor, A. (2022). Combination Approaches to Target PD-1 Signaling in Cancer. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.927265

Alhesa, A., Awad, H., Bloukh, S., Al-Balas, M., El-Sadoni, M., Qattan, D., Azab, B., & Saleh, T. (2022). PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy. International Journal of Immunopathology and Pharmacology, 36. https://doi.org/10.1177/03946320221078433

Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., Ladany, H., Chen, D., Zatzman, M., Cabric, V., Nobre, L., Bianchi, V., Edwards, M., Sambira Nahum, L. C., Ercan, A. B., … Tabori, U. (2022). Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 28(1), 125–135. https://doi.org/10.1038/s41591-021-01581-6